Health & Biotech
MGC Pharmaceuticals (ASX:MXC) is a global biopharma company focused on developing and supplying high-quality phytotherapeutics and phytomedicines to patients in Europe, Australasia, and North America. The company’s current phytomedicine range includes CannEpil, an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, and CogniCann, a treatment to improve quality of life in dementia patients. Both products are certified as Investigational Medical Products in the EU, and emerge from MGC’s euGMP formulation facility.
MGC has a full seed to pharma operation, from proprietary genetics through to the final phytomedicines undergoing clinical trials and produced under the strictest manufacturing conditions in the world. Because of this full hold on the supply chain, MGC is also a supplier of multiple phytocannabinoid products, from genetics via seed or tissue culture , through cosmetics and nutraceuticals, all the way to final medications, and phytocannabinoid active pharmaceutical ingredients (API).
MGC has established licensed growing operations in the Czech Republic and Slovenia, a fully GMP certified resin extraction plant in Slovenia, and was the first company approval from the Maltese government to build a local medical cannabis cultivation and production facility.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
CEOs look back and share their company highlights from 2021
News
CEOs look back and share the most important lesson they learnt in 2021
Health & Biotech
What you’ve been vaping for: MGC Pharma now has the first-ever Cannabinoid vape available as an unapproved therapeutic good for use in Australia
Health & Biotech
MGC Pharma secures $10m capital raise from US and UK investors to advance development for its lead drug candidate, CimetrA
Health & Biotech
As Biotron more than doubles on promising COVID results, which other ASX stocks are working on treatments?
Health & Biotech
MGC Pharma set for best half-yearly results after delivering ArtemiC order in Europe
Health & Biotech
MGC Pharma US partnership validated after receiving first payment for US$24m order of CimetrA
Health & Biotech
ASX Health Stocks: Paradigm rockets 21pc after getting FDA nod, Memphasys up 31pc on imminent launch
Health & Biotech
MGC Pharma opens new production facility in Malta, now set to ramp up sales of CimetrA
Health & Biotech
ASX Health Stocks: Intelicare jumps 35pc on AI in-home sensor tech contract for seniors
Health & Biotech
With record growth in 2021, MGC Pharma’s Q1 trading update confirmed it’s laid the foundation for a global expansion
Health & Biotech
MGC Pharma lands milestone US$3 million CimetrA purchase order
Health & Biotech
MGC Pharma receives first order in the US, as it seeks to fast track commercialisation of CimetrA
Health & Biotech
Here’s why this fundie expects MGC Pharma’s stock price to more than double
Health & Biotech
MGC Pharma makes inroads in the fight against COVID-19, getting a regulatory nod in Germany and a successful trial in India
Health & Biotech
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
Health & Biotech